Kristen M. Kokkonen-Simon

Kristen M. Kokkonen-Simon

Auto-generated profile, based on publicly available information

Kristen M. Kokkonen-Simon

Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, 21205, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in Circulation
Verified
Journal Article
Open access
PDF file
SHSteven Hsu
Steven Hsu
KKKristen M. Kokkonen-Simon
Kristen M. Kokkonen-Simon
JKJonathan A. Kirk
Jonathan A. Kirk
TKTodd M. Kolb
Todd M. Kolb
RDRachel L. Damico
Rachel L. Damico
DKDavid A. Kass
David A. Kass
Background: Patients with systemic sclerosis (SSc)–associated pulmonary arterial hypertension (PAH) have a far worse prognosis than those with idiopathic PAH (IPAH). In the intact heart, SSc-PAH exhibits depressed rest and reserve right ventricular (RV) contractility compared with IPAH. We tested whether this disparity involves underlying differences in myofilament function. Methods: Cardiac myocytes were isolated from RV septal endomyocardial biopsies from patients with SSc-PAH, IPAH, or SSc with exertional dyspnea but no resting PAH (SSc-d); control RV septal tissue was obtained from nondiseased donor hearts (6–7 per group). Isolated myocyte passive length-tension and developed tension-calcium relationships were determined and correlated with in vivo RV function and reserve. RV septal fibrosis was also examined. Results: Myocyte passive stiffness from length-tension relations was similarly increased in IPAH and SSc-PAH compared with control, although SSc-PAH biopsies had more interstitial fibrosis. More striking disparities were found between active force-calcium relations. Compared with controls, maximal calcium-activated force (F max ) was 28% higher in IPAH but 37% lower in SSc-PAH. F max in SSc-d was intermediate between control and SSc-PAH. The calcium concentration required for half-maximal force (EC 50 ) was similar between control, IPAH, and SSc-d but lower in SSc-PAH. This disparity disappeared in myocytes incubated with the active catalytic subunit of protein kinase A. Myocyte F max directly correlated with in vivo RV contractility assessed by end-systolic elastance ( R 2 =0.46, P =0.002) and change in end-systolic elastance with exercise ( R 2 =0.49, P =0.008) and was inversely related with exercise-induced chamber dilation ( R 2 =0.63, P <0.002), which also was a marker of depressed contractile reserve. Conclusions: A primary defect in human SSc-PAH resides in depressed sarcomere function, whereas this is enhanced in IPAH. These disparities correlate with in vivo RV contractility and contractile reserve and are consistent with worse clinical outcomes in SSc-PAH. The existence of sarcomere disease before the development of resting PAH in patients with SSc-d suggests that earlier identification and intervention may prove useful.

30 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
MRMark J. Ranek
Mark J. Ranek
KKKristen M. Kokkonen-Simon
Kristen M. Kokkonen-Simon
ACAnna Chen
Anna Chen
BDBrittany L. Dunkerly-Eyring
Brittany L. Dunkerly-Eyring
MVMiguel Pinilla Vera
Miguel Pinilla Vera
DKDavid A. Kass
David A. Kass

7 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
QZQing-Jun Zhang
Qing-Jun Zhang
TTTram Anh T. Tran
Tram Anh T. Tran
MWMing Wang
Ming Wang
MRMark J. Ranek
Mark J. Ranek
KKKristen M. Kokkonen-Simon
Kristen M. Kokkonen-Simon
ZLZhi-ping Liu
Zhi-ping Liu
Left ventricular hypertrophy (LVH) is a major risk factor for cardiovascular morbidity and mortality. Pathological LVH engages transcriptional programs including reactivation of canonical fetal genes and those inducing fibrosis. Histone lysine demethylases (KDMs) are emerging regulators of transcriptional reprogramming in cancer, though their potential role in abnormal heart growth and fibrosis remains little understood. Here, we investigate gain and loss of function of an H3K9me2 specific demethylase, Kdm3a, and show it promotes LVH and fibrosis in response to pressure-overload. Cardiomyocyte KDM3A activates Timp1 transcription with pro-fibrotic activity. By contrast, a pan-KDM inhibitor, JIB-04, suppresses pressure overload-induced LVH and fibrosis. JIB-04 inhibits KDM3A and suppresses the transcription of fibrotic genes that overlap with genes downregulated in Kdm3a-KO mice versus WT controls. Our study provides genetic and biochemical evidence for a pro-hypertrophic function of KDM3A and proof-of principle for pharmacological targeting of KDMs as an effective strategy to counter LVH and pathological fibrosis.

6 January 2017 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
KKKristen Kokkonen
Kristen Kokkonen
DKDavid A. Kass
David A. Kass
Cyclic nucleotide phosphodiesterases (PDEs) form an 11-member superfamily comprising 100 different isoforms that regulate the second messengers cyclic adenosine or guanosine 3′,5′-monophosphate (cAMP or cGMP). These PDE isoforms differ with respect to substrate selectivity and their localized control of cAMP and cGMP within nanodomains that target specific cellular pools and synthesis pathways for the cyclic nucleotides. Seven PDE family members are physiologically relevant to regulating cardiac function, disease remodeling of the heart, or both: PDE1 and PDE2, both dual-substrate (cAMP and cGMP) esterases; PDE3, PDE4, and PDE8, which principally hydrolyze cAMP; and PDE5A and PDE9A, which target cGMP. New insights regarding the different roles of PDEs in health and disease and their local signaling control are broadening the potential therapeutic utility for PDE-selective inhibitors. In this review, we discuss these PDEs, focusing on the different mechanisms by which they control cardiac function in health and disease by regulating intracellular nanodomains.

20 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MRMark J. Ranek
Mark J. Ranek
COChristian Oeing
Christian Oeing
RSRebekah Sanchez-Hodge
Rebekah Sanchez-Hodge
KKKristen M. Kokkonen-Simon
Kristen M. Kokkonen-Simon
DDDanielle Dillard
Danielle Dillard
DKDavid A. Kass
David A. Kass
Proteotoxicity from insufficient clearance of misfolded/damaged proteins underlies many diseases. Carboxyl terminus of Hsc70-interacting protein (CHIP) is an important regulator of proteostasis in many cells, having E3-ligase and chaperone functions and often directing damaged proteins towards proteasome recycling. While enhancing CHIP functionality has broad therapeutic potential, prior efforts have all relied on genetic upregulation. Here we report that CHIP-mediated protein turnover is markedly post-translationally enhanced by direct protein kinase G (PKG) phosphorylation at S20 (mouse, S19 human). This increases CHIP binding affinity to Hsc70, CHIP protein half-life, and consequent clearance of stress-induced ubiquitinated-insoluble proteins. PKG-mediated CHIP-pS20 or expressing CHIP-S20E (phosphomimetic) reduces ischemic proteo- and cytotoxicity, whereas a phospho-silenced CHIP-S20A amplifies both. In vivo, depressing PKG activity lowers CHIP-S20 phosphorylation and protein, exacerbating proteotoxicity and heart dysfunction after ischemic injury. CHIP-S20E knock-in mice better clear ubiquitinated proteins and are cardio-protected. PKG activation provides post-translational enhancement of protein quality control via CHIP.

1 March 2018 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
NTNakamura Taishi
Nakamura Taishi
GZGuangshuo Zhu
Guangshuo Zhu
MRMark J. Ranek
Mark J. Ranek
KKKristen Kokkonen-Simon
Kristen Kokkonen-Simon
MZManling Zhang
Manling Zhang
DKDavid A. Kass
David A. Kass
Background: Stimulation of sGC (soluble guanylate cyclase) or inhibition of PDE5 (phosphodiesterase type 5) activates PKG (protein kinase G)-1α to counteract cardiac hypertrophy and failure. PKG1α acts within localized intracellular domains; however, its oxidation at cysteine 42, linking homomonomers, alters this localization, impairing suppression of pathological cardiac stress. Because PDE5 and sGC reside in separate microdomains, we speculated that PKG1α oxidation might also differentially influence the effects from their pharmacological modulation. Methods and Results: Knock-in mice expressing a redox-dead PKG1α (PKG1α C42S ) or littermate controls (PKG1α WT ) were subjected to transaortic constriction to induce pressure overload and treated with a PDE5 inhibitor (sildenafil), sGC activator (BAY602770 [BAY]), or vehicle. In PKG1α WT controls, sildenafil and BAY similarly enhanced PKG activity and reduced pathological hypertrophy/fibrosis and cardiac dysfunction after transaortic constriction. However, sildenafil failed to protect the heart in PKG1α C42S , unlike BAY, which activated PKG and thereby facilitated protective effects. This corresponded with minimal PDE5 activation in PKG1α C42S exposed to transaortic constriction versus higher activity in controls and little colocalization of PDE5 with PKG1α C42S (versus colocalization with PKG1α WT ) in stressed myocytes. Conclusions: In the stressed heart and myocytes, PKG1α C42-disulfide formation contributes to PDE5 activation. This augments the pathological role of PDE5 and so in turn enhances the therapeutic impact from its inhibition. PKG1α oxidation does not change the benefits from sGC activation. This finding favors the use of sGC activators regardless of PKG1α oxidation and may help guide precision therapy leveraging the cyclic GMP/PKG pathway to treat heart disease.